Clinical Trial Update: Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 [Phase 3]

View source ↗

Summary

A Phase 3 study screening protocol for the CCR5 antagonist GW873140 in HIV infection has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GW873140

Snippet

Sponsor: GlaxoSmithKline | Conditions: HIV Infection | Phase 3 | Status: TERMINATED